Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Camouflage makeup improves quality of life in cancer patients with treatment-related skin changes.

Wakeda T, Okamura T, Kawahara T, Heike Y.

Tumori. 2019 Aug 9:300891619867844. doi: 10.1177/0300891619867844. [Epub ahead of print]

PMID:
31394967
2.

The association between consuming bivalves, and acute gastroenteritis and norovirus in Tokyo, Japan.

Kobayashi D, Saito M, Heike Y, Yokota K, Arioka H, Oshitani H.

J Med Virol. 2019 Jun;91(6):986-996. doi: 10.1002/jmv.25416. Epub 2019 Feb 7.

PMID:
30698827
3.

The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy.

Shoji H, Tada K, Kitano S, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Takashima A, Kato K, Boku N, Honda K, Yamada T, Heike Y, Hamaguchi T.

Oncotarget. 2017 May 30;8(56):95083-95094. doi: 10.18632/oncotarget.18297. eCollection 2017 Nov 10.

4.

Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome.

Ueda Y, Ogura M, Miyakoshi S, Suzuki T, Heike Y, Tagashira S, Tsuchiya S, Ohyashiki K, Miyazaki Y.

Cancer Sci. 2017 Dec;108(12):2445-2453. doi: 10.1111/cas.13409. Epub 2017 Oct 25.

5.

A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia.

Kobayashi Y, Sakura T, Miyawaki S, Toga K, Sogo S, Heike Y.

Cancer Immunol Immunother. 2017 Jul;66(7):851-863. doi: 10.1007/s00262-017-1981-3. Epub 2017 Mar 20.

6.

Case report of nivolumab-related pneumonitis.

Tada K, Kurihara Y, Myojo T, Kojima F, Ishikawa Y, Yoshiyasu N, Morimoto M, Ito R, Koyamada R, Yamashita T, Bando T, Mori S, Heike Y.

Immunotherapy. 2017 Mar;9(4):313-318. doi: 10.2217/imt-2016-0129.

PMID:
28303763
7.

CTIA-4 blockade therapy; biology and clinical activity.

Tada K, Heike Y.

Nihon Rinsho. 2017 Feb;75(2):196-200. Japanese.

PMID:
30562852
8.

Prognostic significance of HLA class I and II expression in patients with diffuse large B cell lymphoma treated with standard chemoimmunotherapy.

Tada K, Maeshima AM, Hiraoka N, Yamauchi N, Maruyama D, Kim SW, Watanabe T, Katayama N, Heike Y, Tobinai K, Kobayashi Y.

Cancer Immunol Immunother. 2016 Oct;65(10):1213-22. doi: 10.1007/s00262-016-1883-9. Epub 2016 Aug 13.

PMID:
27522583
9.

Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients.

Tada K, Kitano S, Shoji H, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Yamada Y, Katayama N, Boku N, Heike Y, Hamaguchi T.

Cancer Immunol Res. 2016 Jul;4(7):592-9. doi: 10.1158/2326-6066.CIR-15-0298. Epub 2016 Apr 28.

10.

Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients.

Iwasa S, Yamada Y, Heike Y, Shoji H, Honma Y, Komatsu N, Matsueda S, Yamada A, Morita M, Yamaguchi R, Tanaka N, Kawahara A, Kage M, Shichijo S, Sasada T, Itoh K.

Cancer Sci. 2016 May;107(5):590-600. doi: 10.1111/cas.12919. Epub 2016 Apr 26.

11.

Assessment of Relationship between Wilms' Tumor Gene (WT1) Expression in Peripheral Blood of Acute Leukemia Patients and Serum IL-12 and C3 Levels.

Rezai O, Khodadadi A, Heike Y, Mostafai A, Gerdabi ND, Rashno M, Abdoli Z.

Asian Pac J Cancer Prev. 2015;16(16):7303-7.

12.

Donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene: detailed immunological function following add-back after haplo-identical transplantation.

Hashimoto H, Kitano S, Yamagata S, Miyagi Maeshima A, Ueda R, Ito A, Tada K, Fuji S, Yamashita T, Tomura D, Nukaya I, Mineno J, Fukuda T, Mori S, Takaue Y, Heike Y.

Cytotherapy. 2015 Dec;17(12):1820-30. doi: 10.1016/j.jcyt.2015.08.005. Epub 2015 Oct 6.

PMID:
26452983
13.

Erratum to: Infusion of donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene for recurrent hematologic malignancies after allogeneic hematopoietic stem cell transplantation.

Hashimoto H, Kitano S, Ueda R, Ito A, Tada K, Fuji S, Kim SW, Yamashita T, Tomura D, Nukaya I, Mineno J, Fukuda T, Mori S, Takaue Y, Heike Y.

Int J Hematol. 2015 Oct;102(4):506. doi: 10.1007/s12185-015-1866-1. No abstract available.

PMID:
26362857
14.

Infusion of donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene for recurrent hematologic malignancies after allogeneic hematopoietic stem cell transplantation.

Hashimoto H, Kitano S, Ueda R, Ito A, Tada K, Fuji S, Yamashita T, Tomura D, Nukaya I, Mineno J, Fukuda T, Mori S, Takaue Y, Heike Y.

Int J Hematol. 2015 Jul;102(1):101-10. doi: 10.1007/s12185-015-1801-5. Epub 2015 May 7. Erratum in: Int J Hematol. 2015 Oct;102(4):506.

PMID:
25948083
15.

Type I IFN gene delivery suppresses regulatory T cells within tumors.

Hashimoto H, Ueda R, Narumi K, Heike Y, Yoshida T, Aoki K.

Cancer Gene Ther. 2014 Dec;21(12):532-41. doi: 10.1038/cgt.2014.60. Epub 2014 Nov 28.

PMID:
25430879
16.

Wilms' tumor gene (WT1) expression correlates with vascular epithelial growth factor (VEGF) in newly acute leukemia patients undergoing chemotherapy.

Iranparast S, Assarehzadegan MA, Heike Y, Hossienzadeh M, Khodadadi A.

Asian Pac J Cancer Prev. 2014;15(21):9217-23.

17.

A higher number of infused CD34(+) cells has a positive impact on the clinical outcome after related PBSC transplantation.

Maie K, Fuji S, Tajima K, Tatsuno M, Yamagata S, Takahashi N, Ueda R, Hashimoto H, Takano K, Inoue Y, Ito A, Hayashi Y, Okinaka K, Kurosawa S, Kim SW, Tanosaki R, Heike Y, Yamashita T, Fukuda T.

Bone Marrow Transplant. 2014 Aug;49(8):1113-5. doi: 10.1038/bmt.2014.94. Epub 2014 May 5. No abstract available.

PMID:
24797181
18.

Novel and rapid enumeration method of peripheral blood stem cells using automated hematology analyzer.

Tanosaki R, Kumazawa T, Yoshida A, Oguni S, Nakano A, Yamagata S, Takahashi N, Kurosawa S, Kim SW, Yamashita T, Mori S, Heike Y, Fukuda T, Hamaguchi Y, Tsuda H.

Int J Lab Hematol. 2014 Oct;36(5):521-30. doi: 10.1111/ijlh.12182. Epub 2013 Dec 27.

PMID:
24373185
19.

Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients.

Hiramoto N, Kurosawa S, Tajima K, Okinaka K, Tada K, Kobayashi Y, Shinohara A, Inoue Y, Ueda R, Tanaka T, Kim SW, Yamashita T, Heike Y, Fukuda T.

Eur J Haematol. 2014 Feb;92(2):137-46. doi: 10.1111/ejh.12214. Epub 2013 Nov 9.

PMID:
24127668
20.

Reduced-intensity conditioning regimen with low-dose ATG-F for unrelated bone marrow transplant is associated with lower non-relapse mortality than a regimen with low-dose TBI: a single-center retrospective analysis of 103 cases.

Fuji S, Ueno N, Hiramoto N, Asakura Y, Yakushijin K, Kamiyama Y, Kurosawa S, Kim SW, Heike Y, Yamashita T, Fukuda T.

Int J Hematol. 2013 Nov;98(5):608-14. doi: 10.1007/s12185-013-1449-y. Epub 2013 Oct 4.

PMID:
24092050
21.

Diagnosis and evaluation of intestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation following reduced-intensity and myeloablative conditioning regimens.

Yamasaki S, Miyagi-Maeshima A, Kakugawa Y, Matsuno Y, Ohara-Waki F, Fuji S, Morita-Hoshi Y, Mori M, Kim SW, Mori S, Fukuda T, Tanosaki R, Shimoda T, Tobinai K, Saito D, Takaue Y, Teshima T, Heike Y.

Int J Hematol. 2013 Mar;97(3):421-6. doi: 10.1007/s12185-013-1297-9. Epub 2013 Feb 23.

PMID:
23435651
22.

Carcinoma of donor origin after allogeneic peripheral blood stem cell transplantation.

Munakata W, Nomoto J, Takahashi N, Taniguchi H, Maeshima AM, Asamura H, Tanosaki R, Heike Y, Fukuda T, Tobinai K, Kobayashi Y.

Am J Surg Pathol. 2012 Sep;36(9):1376-84. doi: 10.1097/PAS.0b013e318261089c.

PMID:
22895271
23.

Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma.

Tada K, Kim SW, Asakura Y, Hiramoto N, Yakushijin K, Kurosawa S, Tajima K, Mori S, Heike Y, Tanosaki R, Maeshima AM, Taniguchi H, Furuta K, Kagami Y, Matsuno Y, Tobinai K, Takaue Y, Fukuda T.

Am J Hematol. 2012 Aug;87(8):770-5. doi: 10.1002/ajh.23246. Epub 2012 May 28.

24.

Stenotrophomonas maltophilia infection in hematopoietic SCT recipients: high mortality due to pulmonary hemorrhage.

Tada K, Kurosawa S, Hiramoto N, Okinaka K, Ueno N, Asakura Y, Kim SW, Yamashita T, Mori SI, Heike Y, Maeshima AM, Tanosaki R, Tobinai K, Fukuda T.

Bone Marrow Transplant. 2013 Jan;48(1):74-9. doi: 10.1038/bmt.2012.87. Epub 2012 May 28.

PMID:
22635245
25.

Real-time in vivo cellular imaging of graft-versus-host disease and its reaction to immunomodulatory reagents.

Yamazaki T, Aoki K, Heike Y, Kim SW, Ochiya T, Wakeda T, Hoffman RM, Takaue Y, Nakagama H, Ikarashi Y.

Immunol Lett. 2012 May 30;144(1-2):33-40. doi: 10.1016/j.imlet.2012.03.004. Epub 2012 Mar 15.

PMID:
22426442
27.

Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.

Kaida M, Morita-Hoshi Y, Soeda A, Wakeda T, Yamaki Y, Kojima Y, Ueno H, Kondo S, Morizane C, Ikeda M, Okusaka T, Takaue Y, Heike Y.

J Immunother. 2011 Jan;34(1):92-9. doi: 10.1097/CJI.0b013e3181fb65b9.

PMID:
21150717
28.

Long-term administration of Wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites.

Soeda A, Morita-Hoshi Y, Kaida M, Wakeda T, Yamaki Y, Kojima Y, Ueno H, Kondo S, Morizane C, Ikeda M, Okusaka T, Heike Y.

Jpn J Clin Oncol. 2010 Dec;40(12):1184-8. doi: 10.1093/jjco/hyq112. Epub 2010 Jul 22.

PMID:
20656693
29.

A potential activity of valproic acid in the stimulation of interleukin-3-mediated megakaryopoiesis and erythropoiesis.

Liu B, Ohishi K, Yamamura K, Suzuki K, Monma F, Ino K, Nishii K, Masuya M, Sekine T, Heike Y, Takaue Y, Katayama N.

Exp Hematol. 2010 Aug;38(8):685-95. doi: 10.1016/j.exphem.2010.03.019. Epub 2010 Apr 8. Erratum in: Exp Hematol. 2010 Sep;38(9):845. Nishii, Kazuhiro [added].

PMID:
20381581
30.

Identification of molecular markers for pre-engraftment immune reactions after cord blood transplantation by SELDI-TOF MS.

Morita-Hoshi Y, Mori SI, Soeda A, Wakeda T, Ohsaki Y, Shiwa M, Masuoka K, Wake A, Taniguchi S, Takaue Y, Heike Y.

Bone Marrow Transplant. 2010 Nov;45(11):1594-601. doi: 10.1038/bmt.2010.18. Epub 2010 Mar 15.

PMID:
20228853
31.

Outcome of 93 patients with relapse or progression following allogeneic hematopoietic cell transplantation.

Kurosawa S, Fukuda T, Tajima K, Saito B, Fuji S, Yokoyama H, Kim SW, Mori S, Tanosaki R, Heike Y, Takaue Y.

Am J Hematol. 2009 Dec;84(12):815-20. doi: 10.1002/ajh.21555.

32.

[Gene therapy for myeloid leukemia].

Heike Y.

Nihon Rinsho. 2009 Oct;67(10):1958-63. Review. Japanese.

PMID:
19860197
33.

Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer.

Soeda A, Morita-Hoshi Y, Makiyama H, Morizane C, Ueno H, Ikeda M, Okusaka T, Yamagata S, Takahashi N, Hyodo I, Takaue Y, Heike Y.

Jpn J Clin Oncol. 2009 Dec;39(12):797-806. doi: 10.1093/jjco/hyp112. Epub 2009 Oct 1.

PMID:
19797418
34.

Decreased insulin secretion in patients receiving tacrolimus as GVHD prophylaxis after allogeneic hematopoietic SCT.

Fuji S, Kim SW, Mori S, Furuta K, Tanosaki R, Heike Y, Takaue Y, Fukuda T.

Bone Marrow Transplant. 2010 Feb;45(2):405-6. doi: 10.1038/bmt.2009.154. Epub 2009 Aug 3. No abstract available.

PMID:
19648969
35.

Intensive glucose control after allogeneic hematopoietic stem cell transplantation: a retrospective matched-cohort study.

Fuji S, Kim SW, Mori S, Kamiya S, Yoshimura K, Yokoyama H, Kurosawa S, Saito B, Takahashi T, Kuwahara S, Heike Y, Tanosaki R, Takaue Y, Fukuda T.

Bone Marrow Transplant. 2009 Jul;44(2):105-11. doi: 10.1038/bmt.2008.431. Epub 2009 Jan 19.

PMID:
19151794
36.

Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma.

Maruyama D, Watanabe T, Heike Y, Nagase K, Takahashi N, Yamasaki S, Waki F, Yokoyama H, Kim SW, Kobayashi Y, Aizawa S, Tobinai K.

Int J Hematol. 2008 Nov;88(4):396-402. doi: 10.1007/s12185-008-0194-0. Epub 2008 Nov 7.

PMID:
18989635
37.

Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen.

Saito B, Fukuda T, Yokoyama H, Kurosawa S, Takahashi T, Fuji S, Takahashi N, Tajima K, Kim SW, Mori SI, Tanosaki R, Takaue Y, Heike Y.

Biol Blood Marrow Transplant. 2008 Oct;14(10):1148-1155. doi: 10.1016/j.bbmt.2008.07.013.

38.

Insufficient ex vivo expansion of Valpha24(+) natural killer T cells in malignant lymphoma patients related to the suppressed expression of CD1d molecules on CD14(+) cells.

Imataki O, Heike Y, Makiyama H, Iizuka A, Ikarashi Y, Ishida T, Wakasugi H, Takaue Y.

Cytotherapy. 2008;10(5):497-506. doi: 10.1080/14653240802072747.

PMID:
18608348
39.

Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.

Fuji S, Kim SW, Fukuda T, Mori S, Yamasaki S, Morita-Hoshi Y, Ohara-Waki F, Heike Y, Tobinai K, Tanosaki R, Takaue Y.

Biol Blood Marrow Transplant. 2008 May;14(5):510-7. doi: 10.1016/j.bbmt.2008.02.008.

40.

Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: a Japanese survey.

Kanda Y, Omuro Y, Baba E, Oshima K, Nagafuji K, Heike Y, Takaue Y, Sasaki T, Sakamaki H, Harada M.

Bone Marrow Transplant. 2008 Jul;42(2):99-103. doi: 10.1038/bmt.2008.94. Epub 2008 Apr 7.

PMID:
18391987
41.

Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens.

Yamasaki S, Heike Y, Mori S, Fukuda T, Maruyama D, Kato R, Usui E, Koido K, Kim S, Tanosaki R, Tobinai K, Teshima T, Takaue Y.

Transpl Infect Dis. 2008 Jul;10(4):252-9. doi: 10.1111/j.1399-3062.2007.00291.x. Epub 2008 Jan 9.

PMID:
18194371
42.

Functional analysis of cytomegalovirus-specific T lymphocytes compared to tetramer assay in patients undergoing hematopoietic stem cell transplantation.

Morita-Hoshi Y, Heike Y, Kawakami M, Sugita T, Miura O, Kim SW, Mori SI, Fukuda T, Tanosaki R, Tobinai K, Takaue Y.

Bone Marrow Transplant. 2008 Mar;41(6):515-21. Epub 2007 Nov 19.

PMID:
18026143
43.

Interleukin (IL)-4 promotes T helper type 2-biased natural killer T (NKT) cell expansion, which is regulated by NKT cell-derived interferon-gamma and IL-4.

Iizuka A, Ikarashi Y, Yoshida M, Heike Y, Takeda K, Quinn G, Wakasugi H, Kitagawa M, Takaue Y.

Immunology. 2008 Jan;123(1):100-7. Epub 2007 Nov 14.

44.

Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation.

Fuji S, Kim SW, Mori S, Fukuda T, Kamiya S, Yamasaki S, Morita-Hoshi Y, Ohara-Waki F, Honda O, Kuwahara S, Tanosaki R, Heike Y, Tobinai K, Takaue Y.

Transplantation. 2007 Oct 15;84(7):814-20.

PMID:
17984832
45.

T-cell large granular lymphocyte leukemia of donor origin after cord blood transplantation.

Kusumoto S, Mori S, Nosaka K, Morita-Hoshi Y, Onishi Y, Kim SW, Watanabe T, Heike Y, Tanosaki R, Takaue Y, Tobinai K.

Clin Lymphoma Myeloma. 2007 Jul;7(7):475-9.

PMID:
17875238
46.

Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.

Maruyama D, Fukuda T, Kato R, Yamasaki S, Usui E, Morita-Hoshi Y, Kim SW, Mori S, Heike Y, Makimoto A, Tajima K, Tanosaki R, Tobinai K, Takaue Y.

Biol Blood Marrow Transplant. 2007 Aug;13(8):932-41. Epub 2007 May 29.

47.

Unrelated-donor bone marrow transplantation with a conditioning regimen including fludarabine, busulfan, and 4 Gy total body irradiation.

Onishi Y, Mori S, Kusumoto S, Sugimoto K, Akahane D, Morita-Hoshi Y, Kim SW, Fukuda T, Heike Y, Tanosaki R, Tobinai K, Takaue Y.

Int J Hematol. 2007 Apr;85(3):256-63.

PMID:
17483064
48.

Early detection of plasma cytomegalovirus DNA by real-time PCR after allogeneic hematopoietic stem cell transplantation.

Onishi Y, Mori S, Higuchi A, Kim SW, Fukuda T, Heike Y, Tanosaki R, Minematsu T, Takaue Y, Sasaki T, Furuta K.

Tohoku J Exp Med. 2006 Oct;210(2):125-35.

49.

Pleiotropic role of histone deacetylases in the regulation of human adult erythropoiesis.

Yamamura K, Ohishi K, Katayama N, Yu Z, Kato K, Masuya M, Fujieda A, Sugimoto Y, Miyata E, Shibasaki T, Heike Y, Takaue Y, Shiku H.

Br J Haematol. 2006 Oct;135(2):242-53. Epub 2006 Aug 25. Erratum in: Br J Haematol. 2007 Jan;136(1):175-6.

PMID:
16939493
50.

Modulation of acute graft-versus-host disease and chimerism after adoptive transfer of in vitro-expanded invariant Valpha14 natural killer T cells.

Kuwatani M, Ikarashi Y, Iizuka A, Kawakami C, Quinn G, Heike Y, Yoshida M, Asaka M, Takaue Y, Wakasugi H.

Immunol Lett. 2006 Jul 15;106(1):82-90. Epub 2006 May 23.

PMID:
16806496

Supplemental Content

Support Center